GSK Pharma Drops 7% on Q1 Miss

  Published 8 months ago

GSK Pharma stock slid 6.7% after Q1 revenue dipped 1.2%, its first drop since March 2023.

  • Revenue fell to Rs 8.05 billion due to seasonal disruption, missing expectations per the company statement.
  • Stock on track for biggest single-day fall since March 2020, with volume 1.5x the 30-day average.
  • Despite Q1 miss, GLAX shares remain up 31% year-to-date, reflecting strong earlier performance.

You might like these

IndiGo Co-founder Sells $1.4B Stake

Coforge Shares Hit 3-Month Low

Zydus Wins US Nod for Celecoxib

India's Service Sector Hits 10-Month Growth High in June

Tata Communications Outperform Rating & Growth Outlook

Market Buzz: Q1 Earnings & F&O Update

MoSPI Plans CPI Housing Index Overhaul

News that matters the most ⚡